News Search Results
Feb 12, 2026, 10:45 ET Centivax Initiates Phase 1 First-in-Human Clinical Trial of Universal Flu Vaccine
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 /PRNewswire/ -- Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced that the first participants
More news about: Centivax
Feb 12, 2026, 10:00 ET Yosemite Announces More Than $18 Million Deployed in Grants
example included preclinical research led by Craig Crews at Yale, which contributed to foundational insights behind the formation of Quarry Thera, a biotechnology company developing small molecule drugs that modulate protein interactions in completely novel ways to treat cancer and autoimmune diseases.Collaboration
More news about: Yosemite
Feb 12, 2026, 09:30 ET Timken Awards Scholarships Valued at up to $540,000 to 20 Students Around the World
Sylwester Struski and Edyta Struska from Czeladź, Poland. She plans to study medicine at the Medical University of Wrocław, specializing in surgery or biotechnology.Lana Mary Tom, daughter of senior system consultant Tom Chandy and Jyothi Jose from Christ Junior College in Bangalore, India. She
More news about: The Timken Company
Feb 12, 2026, 09:00 ET Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide
advancing toward the automated future of "lights-out laboratories."The industry widely recognizes that the deep integration of AI technology and biotechnology represents a key direction for the future of pharmaceutical R&D. In response, Sanyou Biopharmaceuticals is committed to building an intelligent
More news about: Sanyou Bio
Feb 12, 2026, 09:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Feb 12, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., Feb. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Feb 12, 2026, 08:00 ET Apertura Gene Therapy Launches Open Aperture, a Material Transfer Agreement Program to Facilitate Non-Commercial Access to TfR1 CapX for Academic Researchers
—NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced the launch of Open Aperture, a material transfer
More news about: Apertura Gene Therapy
Feb 12, 2026, 07:30 ET Soligenix Details Recent Progress and Upcoming Milestones
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Feb 12, 2026, 06:59 ET Microbiology Testing Market worth $10.09 billion by 2031 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=187005691 Microbiology testing is widely used across pharmaceutical manufacturing, biotechnology, food and beverage processing, water quality monitoring, and environmental applications. Market expansion is driven by rising demand for contamination
More news about: MarketsandMarkets
Feb 11, 2026, 23:18 ET Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
more effective and better-tolerated treatment options for patients living with IPF.About ArkBioArkBio is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory and pediatric diseases. Founded in 2014, the company
More news about: Arkbio
Feb 11, 2026, 23:18 ET Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
more effective and better-tolerated treatment options for patients living with IPF.About ArkBioArkBio is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory and pediatric diseases. Founded in 2014, the company
More news about: Arkbio
Feb 11, 2026, 22:23 ET Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten
More news about: Nektar Therapeutics
Feb 11, 2026, 20:00 ET ToolGen Enters 'Harvest Season' for Global IP Monetization; Appoints Litigation & Negotiation Expert Dave Koo as CLO
Associate at Baker & McKenzie and Paul HastingsLed victories and high-value settlements in major patent disputes among global ICT and biotechnology leaders, including semiconductors, displays, and next-generation light source technologies.Admissions Member
More news about: ToolGen
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Bayer, A2 Biotherapeutics, BioNTech, Dragonfly Therapeutics, Merus, Taiho Oncology, BeOne Medicines (formerly BeiGene), Ono Pharmaceutical, Avistone Biotechnology, Dizal Pharmaceuticals, Checkpoint Therapeutics, DEKA Biosciences, and Taiho Oncology among others.
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 12:27 ET Jennifer Laucirica Named Co-Chair of Trusts & Estates Department at Rubin Rudman
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Feb 11, 2026, 12:16 ET Trescal Reaffirms Dominance in Calibration Sector
coast: Silicon Valley, California, and Melbourne, Florida.Silicon Valley laboratory is tailored to the rigorous compliance needs of the biotechnology, pharmaceutical, and medical device sectors. It offers ISO 17025 accredited services specifically for the instrumentation critical to GxP environments,
More news about: Trescal
Feb 11, 2026, 10:50 ET Genomics Market to Reach $97.1 Billion by 2033 Globally, at 11.5% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/connect-to-analyst/5474The pharmaceutical and biotechnology companies segment generated the highest revenue in 2023By end user, pharmaceutical and biotechnology companies accounted for the largest revenue share in 2023. These companies extensively utilize
More news about: Allied Market Research
Feb 11, 2026, 09:00 ET Decoy Therapeutics Joins Webull Corporate Connect Service Platform
https://www.webullcorp.com/About Decoy Therapeutics, Inc.Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate
More news about: Decoy Therapeutics, Inc
Feb 11, 2026, 08:43 ET Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website
Feb. 11, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced the completion of its corporate name
More news about: AVAI Bio Inc.
Feb 11, 2026, 08:00 ET Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug
More news about: Evogene; Systasy; LMU University Hospital Munich
Feb 11, 2026, 08:00 ET Crystalys Therapeutics Appoints Tim Walbert, Former Horizon Therapeutics CEO, as Independent Board Director
development and launch of HUMIRA across multiple indications, and has previously served on the boards of leading industry organizations including the Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA)."Tim's experience developing and commercializing
More news about: Crystalys Therapeutics
Feb 11, 2026, 04:01 ET Algae Products Market Growing at 7.17% CAGR to 2031 with North America Accounting for 34.02% Revenue Share Due to Rising Veganism, Reports Mordor Intelligence
Personal Care and Feed: Expanding beyond the food sector, the algae products market size is being bolstered by high-margin applications in marine biotechnology and aquaculture. Cosmetic brands are increasingly replacing synthetic actives with algae-derived peptides and antioxidants for premium anti-aging
More news about: Mordor Intelligence Private Limited
Feb 11, 2026, 03:50 ET ArisGlobal Announces XDI NavaX Data Intelligence, Three New Agents, and NavaX Translation
transform compliance into a strategic advantage. ArisGlobal serves more than 300 customers globally, including many of the world's top pharmaceutical, biotechnology, and medical device companies. For more information, visit
More news about: ArisGlobal
Feb 11, 2026, 03:30 ET AmacaThera Named Life Sciences Ontario Emerging Company of the Year
this foundation, AmacaThera leverages its proprietary hydrogel platform to co-develop innovative drug delivery solutions with pharmaceutical and biotechnology partners. The platform's inherent versatility enables the creation of long-acting formulations that enhance therapeutic efficacy, improve patient
More news about: AmacaThera
Feb 11, 2026, 03:17 ET ArisGlobal Announces XDI NavaX Data Intelligence, Three New Agents, and NavaX Translation
transform compliance into a strategic advantage. ArisGlobal serves more than 300 customers globally, including many of the world's top pharmaceutical, biotechnology, and medical device companies. For more information, visit
More news about: ArisGlobal